ADA guidance also notes benefits of GLP-1 RAs in diabetes patients who also have cardiovascular disease, chronic kidney disease, or obesity-linked complications
Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E (2017) Gender differences in liver disease and the drug-dose gender gap
Emerging role of exosome-mediated intercellular communication in vascular remodeling
Were at a pivotal moment for the obesity management industry, marked by growing interest in GLP-1 treatments that pair medication with longer-term behavioral and clinical support, noted Kevin Heath, CEO of Pharmacy2U in a company press release
Cuccurazzu B, Bortolotto V, Valente MM, et al
Their published outcome data shows 9.8% average weight loss among VIP members and 800,000+ pounds collectively lost across the membership, with over 150,000 active members